In a test tube at a Dallas research center, molecules once invisible to ordinary sight were seen gathering into droplets, much like oil beading up in water. The work, from Zhijian Chen's laboratory, reveals how the machinery that rouses the body's immune defenses organizes itself within living cells, forming tiny compartments that concentrate the proteins doing the work. It answers a question his group had carried for more than two decades: how the chains, the NEMO protein, and the activating complex find one another. The finding matters because some people are born unable to mount a proper de
Liquid Droplets Inside Cells May Offer New Ways to Tune Immune Activity
Compartments without needing membranes to surround them
Mark
So what's actually new here? The immune pathway was already known.
Mimi
The pathway was, but not how the pieces met. Chen's lab found the ubiquitin chains decades ago. Now they've shown NEMO and those chains condense into liquid droplets, and that's where IKK gets activated.
Mark
Why does a droplet matter versus just proteins floating around?
Mimi
Chen calls them microreactors. They concentrate proteins and their substrates without a membrane around them, so the signal can fire more efficiently.
Luke
Careful, though. "Microreactor" is Chen's interpretation. What was observed is that droplets form and that IKK activation and NF-κB movement follow when IKK enters them.
Mark
And chain length?
Mimi
Longer chains gave bigger droplets and stronger responses. That's a graded relationship, which suggests the system could be turned up or down.
Luke
Suggests, yes. Nothing here shows anyone doing that yet.
Mark
What about the disease angle?
Mimi
NEMO deficiency syndrome mutations kept NEMO from condensing properly with the chains, and the immune cascade didn't start. That links the droplets to a real condition that blunts responses to bacterial infection.
Luke
Worth noting the source doesn't say how many mutations were tested or whether patient cells were used. And the treatment talk is Chen saying it could eventually happen, not a trial.
Mark
So what's the honest takeaway?
Mimi
A mechanism, shown in test tubes and human cells, with a plausible route to future interventions.
Luke
Plausible, not demonstrated. That's the line.
Il Polso
- Two molecules that refused to mix now collect into distinct droplets, and the immune cascade they start depends on how those droplets form.
- Longer ubiquitin chains build larger droplets and stronger responses, so the size of the structure quietly sets the strength of the defense.
- A rare inherited NEMO deficiency blocks droplet formation entirely, tying a laboratory curiosity to a real disease that leaves patients open to infection.
- Researchers are mapping the mechanism now, aiming at therapies for too little or too much immunity, but treatments remain a distant destination rather than an arrived one.
In a test tube at a Dallas research center, molecules once invisible to ordinary sight were seen gathering into droplets, much like oil beading up in water. The work, from Zhijian Chen's laboratory, reveals how the machinery that rouses the body's immune defenses organizes itself within living cells, forming tiny compartments that concentrate the proteins doing the work. It answers a question his group had carried for more than two decades: how the chains, the NEMO protein, and the activating complex find one another. The finding matters because some people are born unable to mount a proper defense, and understanding the physical logic of that assembly may someday offer a way to help them.
In a UT Southwestern laboratory, researchers watched two kinds of molecules gather into droplets that held apart from the liquid around them, the way oil beads in water. The work, published in Molecular Cell, shows how the protein machinery that launches an immune response organizes itself inside cells.
The effort comes from the lab of James Chen, who has spent more than two decades studying how a protein called ubiquitin forms chains inside cells under inflammatory attack. Those chains help activate a complex that includes NEMO, which in turn frees NF-κB to enter the nucleus and switch on hundreds of immune genes. What had remained unclear was how these pieces physically come together. Chen's team found that NEMO and the polyubiquitin chains condense into droplets, and that the process happens in human cells as well as in test tubes. Inside these droplets the activating complex becomes switched on. Longer chains produce larger droplets and stronger responses.
The team also examined NEMO carrying mutations found in a rare deficiency syndrome that leaves people badly vulnerable to bacterial infection. Those mutant proteins could not form the droplets, and the signaling cascade stalled. The link gives the mechanism a human face.
Chen suggests that a deeper understanding of this liquid behavior could one day support treatments for NEMO deficiency and for conditions where immunity runs too hot or too cold. The study describes how the process works, not a cure, and whether the droplets can be tuned to help patients remains the open question ahead.
Inside a test tube at UT Southwestern Medical Center, two kinds of molecules did something their researchers could see with their own eyes: they pulled together into droplets that stayed separate from the liquid around them, the way oil beads up in water. The finding, published in Molecular Cell, describes how the protein machinery that launches an immune response organizes itself inside cells.
The work comes from the lab of Zhijian "James" Chen, Ph.D., a Professor of Molecular Biology and Director of the Center for Inflammation Research at UTSW. He is also a Howard Hughes Medical Institute Investigator, a member of the National Academy of Sciences, and a winner of the 2019 Breakthrough Prize in Life Sciences. Chen describes the droplets as microreactors, compartments that concentrate proteins and the molecules they act on without needing a membrane to enclose them.
The question has a long history in his lab. More than two decades ago, Chen's group found that a protein called ubiquitin links into chains inside cells exposed to inflammatory molecules such as interleukin-1β (IL-1β) or tumor necrosis factor α (TNFα). They showed those chains are key to promoting an immune response, and that they can activate a group of proteins called the IκB complex, or IKK, which includes a component named NEMO. Once active, IKK causes a protein called NF-κB to move into the cell nucleus and switch on hundreds of immune-related genes. What remained unclear was how the polyubiquitin chains, NEMO, and IKK actually come together.
To find out, the team mixed ubiquitin and NEMO in test tubes with TRAF6, a protein that prompts ubiquitin to assemble into chains. NEMO and the polyubiquitin chains condensed into liquid droplets that remained distinct from the surrounding medium. Experiments in human cells showed the same behavior, known as phase separation, after the cells were exposed to IL-1β or TNFα.
The droplets mattered functionally. When IKK entered them, it became activated and triggered NF-κB to move to the nucleus. Chen explained that chain length shaped the outcome: the longer the polyubiquitin chains, the larger the droplets they formed with NEMO, and the stronger the immune response that followed.
The researchers also tested NEMO carrying mutations linked to NEMO deficiency syndrome, a rare disease that severely blunts the immune response to bacterial infections. NEMO with these mutations could not effectively condense into droplets with polyubiquitin chains, which stopped the cascade of events that sets off an immune response.
That result ties the droplet behavior directly to a human disease. Chen noted that a better grasp of this liquid phase separation could eventually lead to treatments for NEMO deficiency syndrome, as well as ways to counteract overactive or underactive immunity. Those two conditions underlie autoimmune disorders and heightened susceptibility to infection, respectively. Such therapies remain future work; the study itself describes mechanism, not treatment.
Mingjian Du, Ph.D., a postdoctoral fellow in the Chen lab, is lead author. Chee-Kwee Ea and Yan Fang, also of UTSW, contributed. The research was supported by grants from the Cancer Prevention and Research Institute of Texas (RP180725, RP210041) and The Welch Foundation (I-1389). What to watch next is whether the droplet mechanism can be tuned in ways that help patients with too much or too little immune activity.
Citazioni salienti
The droplets function as microreactors that concentrate proteins and their substrates, forming compartments without membranes around them.— Zhijian "James" Chen, Ph.D., UT Southwestern
Vuoi la storia completa?
Leggi l'originale su News-Medical.net ↗
Science & Space